WHO päivitti Sars-2 viruksen kiertävät VOI ja VUM variantit 6.4. 2023

WHO UPDATE 6.3. 2023
Table 2. Weekly prevalence of SARS-CoV-2 VOIs and VUMs,

week 7 to week 11 of 2023
Lineage Countries Sequences

2023-w.07 , 2023-w.08 , 2023-w.09 , 2023-w.10 , and 2023-w.11 resp. .
XBB.1.5* (VOI)

94 countries, 139 228 seq.

39.83 % ,43.61%, 45.97%, 48.32 % and resp. 47.14%.

BA.2.75* (VUM)

121 countries, 102 656 seq.,

6.05%, 5.87%, 5.16%, 2.84 %, and 1.59% resp.,

CH.1.1* (VUM)

88 copuntries, 38 888 seq.,

6.91 %, 6.70%, 6.50%, 5.80 % and 5.04% resp.,

BQ.1* (VUM)

142 countries, 406 210 seqiuences,

18.68%, 14.79%, 11.07%, 8.52% and 6.92% resp.,

XBB* (VUM)

122 countries, 74 221 seq.,

5.52%, 6.69%, 8.16%, 11.80% and 15.26% resp.

XBB.1.9.1*(VUM),

59 countries, 8212 sequences,

2.03%, 2.96%, 4.26%, 5.46% and 5.96% resp.,

XBF* (VUM),

48 countries, 8505 sequences,

1.25 1.24 1.10 1.26 0.87

Unassigned

96 countrties, 292 690 sequences,

9.17%, 8.99%, 10.91%, 10.28% and 13.77 resp.,

Other+ +Others are other circulating lineages excluding the VOI, VUMs, BA.1*, BA.2*, BA.3*, BA.4*, BA.5*

207 countries, 6 690 563 seq.,

1.28%, 1.10%, 1.12%, 1.05 % and 1.02% resp.,

XBB.1.(VUM),

16 countries (§) , 27 1497 sequences,

0.12 %, 0.25%, 0.60 %, 1.32% and 2.15% resp.,

(§The prevalence of XBB.1.16 was extracted from GISAID on 5 April 2023 using the nucleotides T12730A, T28297C, A28447G).

*Denotes descendent lineages.

.
Additional resources
• Tracking SARS-CoV-2 Variants
• WHO statement on updated tracking system on SARS-CoV-2 variants of concern and variants of interest
• WHO XBB.1.5 rapid risk assessment, 24 February 2023
• Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health
• VIEW-hub: repository for the most relevant and recent vaccine data

SARS-CoV-2 variants of interest and variants under monitoring

Geographic spread and prevalence
Globally, from 5 March to 2 April 2023 (28 days), 65 864 SARS-CoV-2 sequences were shared through GISAID.

Currently, WHO is closely tracking one variant of interest (VOI), XBB.1.5, 

and seven variants under monitoring
(VUMs). 

The VUMs are BA.2.75, CH.1.1, BQ.1, XBF, XBB, XBB.1.16, and XBB.1.9.1.  

On 30 March 2023, XBB.1.9.1 wasadded to the list of VUMs due to the F486P mutation (shared with XBB.1.5 and XBB.1.16). XBB.1.16 and XBB.1.9.1 have the same spike mutation profile as XBB.1.5 (E180V and F486P); and additional mutations in the open reading
frame regions, the effects of which are not well characterized. Mutations at position 478 of the SARS-CoV-2 spike protein have been associated with decreased antibody neutralization, increased transmissibility, and pathogenicity. 

 As of 2 April, a total of 1497 XBB.1.16 and 9644 sequences XBB.1.9.1 have been reported from 27 and 68 countries, respectively.

To date, there have been no reports of higher severity for the currently circulating variants, although some countries have reported an increase in hospitalizations following a rise in case incidence. However, there have been no reported rises in ICU admissions or deaths due to any of the currently circulating XBB descendent lineages. 

 There are currently no reported laboratory studies on markers of disease severity for XBB.1.5, XBB.1.16 or XBB.1.9.1.

Globally, XBB.1.5 accounted for 47.1% of cases in epidemiological week 11 (13 to 19 March 2023), compared to 39.8% in week 7 (13 to 19 February 2023). To date, XBB.1.5 has been detected in 94 countries. 

A comparison of sequences submitted to GISAID from week 7 to week 11 shows declining trends for all VUMs except for XBB, XBB.1.16, and XBB.1.9.1. 

Table 2 shows the number of countries reporting the VOI and VUMs, and their prevalence
from week 7 to week 11